BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Consolidated Statements of Cash Flows
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three months ended | ||||||
| · · March 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flows from operating activities: · · · · | ||||||
| | | | | | | |
| Net loss | | $(2,127) | | $(2,864) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation | | | 37 | | | 52 |
| Stock-based compensation related to options granted to employees and directors | | | 133 | | | 717 |
| Change in operating lease liability | | | 2 | | | 4 |
| Decrease (increase) in other accounts receivable and prepaid expenses | | | 109 | | | (490) |
| Increase in accounts payable | | | 250 | | | 717 |
| Increase in interest expense | | | 82 | | | — |
| Change in fair value of warrant liability | | | — | | | 179 |
| Increase in employees related liability and accrued expenses | | | 194 | | | 412 |
| Net cash used in operating activities | | $(1,320) | | $(1,631) | ||
| Cash flows from financing activities: | | | | | ||
| Proceeds from issuance of shares in at-the-market (ATM) offering (Note 4)(*) | | | — | | | 685 |
| Proceeds from Issuance of shares for private placement (Note 4) (*) | | 970 | | — | ||
| Proceeds from short-term loans (Note 6) | | | 280 | | | 900 |
| Proceeds from warrants issuance (Note 4)(*) | | | — | | | 1,501 |
| Net cash provided by financing activities | | $1,250 | | $3,086 | ||
| Increase (decrease) in cash and cash equivalents | | | (70) | | | 1,455 |
| | | | | | | |
| Cash, cash equivalents and restricted cash at the beginning of the period | | $276 | | $371 | ||
| | | | | | | |
| Cash, cash equivalents and restricted cash at end of the period | | $206 | | $1,826 | ||
(*)Presented after neutralizing costs of issuance.
| · · · · | ||
|---|---|---|
| | | Three months ended |
| | | March 31, |
| · · 2026 · · 2025 | ||
| | | USD in thousands |
| Non-Cash Activities: · · · · | ||
| Reclassifying the warrant liability to equity (Note 4) | — | 268 |
The accompanying notes are an integral part of the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.